NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has entered into definitive agreements with investors to purchase $2.2 million worth of its stock.

Under the registered direct offering, the firm will sell 632,057 ordinary shares at $3.50 per share. The offering is expected to close on or around May 22.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.